-+ 0.00%
-+ 0.00%
-+ 0.00%

Laidlaw & Co. Initiates Coverage On Nasus Pharma with Buy Rating, Announces Price Target of $22

Benzinga·09/29/2025 12:22:01
Listen to the news
Laidlaw & Co. analyst Yale Jen initiates coverage on Nasus Pharma (AMEX:NSRX) with a Buy rating and announces Price Target of $22.